Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Finished Goods (2023 - 2025)

China SXT Pharmaceuticals has reported Finished Goods over the past 3 years, most recently at $448668.0 for Q1 2025.

  • For Q1 2025, Finished Goods fell 18.97% year-over-year to $448668.0; the TTM value through Mar 2025 reached $448668.0, down 18.97%, while the annual FY2025 figure was $448668.0, 18.97% down from the prior year.
  • Finished Goods for Q1 2025 was $448668.0 at China SXT Pharmaceuticals, down from $553682.0 in the prior quarter.
  • Over five years, Finished Goods peaked at $553682.0 in Q1 2024 and troughed at $446866.0 in Q1 2023.
  • A 3-year average of $483072.0 and a median of $448668.0 in 2025 define the central range for Finished Goods.
  • Biggest five-year swings in Finished Goods: grew 23.9% in 2024 and later decreased 18.97% in 2025.
  • Year by year, Finished Goods stood at $446866.0 in 2023, then grew by 23.9% to $553682.0 in 2024, then decreased by 18.97% to $448668.0 in 2025.
  • Business Quant data shows Finished Goods for SXTC at $448668.0 in Q1 2025, $553682.0 in Q1 2024, and $446866.0 in Q1 2023.